Get these analyses to your inbox — https://axialobservations.substack.com/ This is a newsletter for rough-around-the-edges ideas. More well thought out work can be found at — https://axial.substack.com/
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
New medicines #5 — June 6, 2020 — June 12, 2020
A weekly overview of the development of new medicines.
- ADC Therapeutics reported pivotal phase 2 data for their antibody-drug conjugate (ADC) in patients with DLBCL:
- 48.3% ORR
- 24.1% CR
- Interim data on combination with ibrutinib: 75.0% ORR and 58.3% CR at recommended dose
- https://www.businesswire.com/news/home/20200611005918/en/ADC-Therapeutics-Announces-Maturing-Data-Pivotal-Phase
- Agios Pharmaceuticals reported interim phase 2 data for mitapivat in non-transfusion-dependent α- and β-thalassemia:
- Primary endpoint of a sufficient hemoglobin response was met by 12 of 13 (92.3%) patients who had completed 12 weeks of treatment: induced hemoglobin increase of ≥1.0 g/dL
- 7/8 (88%) evaluable patients achieved sustained Hb response (Weeks 12–24)
- https://investor.agios.com…
